GPX 200
Latest Information Update: 28 May 2001
At a glance
- Originator Gem Pharmaceuticals
- Class Cytostatic antibiotics
- Mechanism of Action Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2001 No-Development-Reported for Cancer in USA (Unknown route)
- 01 Jul 1997 New profile
- 01 Jul 1997 Preclinical development for Cancer in USA (Unknown route)